Can-Fite BioPharma (NYSE:CANF) Upgraded at StockNews.com

Posted by Dante Gardener on Oct 25th, 2024

StockNews.com upgraded shares of Can-Fite BioPharma (NYSE:CANF – Free Report) from a sell rating to a hold rating in a report published on Tuesday.

Separately, EF Hutton Acquisition Co. I upgraded shares of Can-Fite BioPharma to a “strong-buy” rating in a report on Wednesday, July 17th.

Check Out Our Latest Stock Analysis on Can-Fite BioPharma

Can-Fite BioPharma Stock Performance

Shares of Can-Fite BioPharma stock opened at $2.51 on Tuesday. Can-Fite BioPharma has a 52 week low of $1.81 and a 52 week high of $4.69. The stock has a 50 day moving average price of $2.30 and a two-hundred day moving average price of $2.51. The stock has a market capitalization of $8.89 million, a PE ratio of -1.40 and a beta of 1.41.

Institutional Trading of Can-Fite BioPharma

A hedge fund recently raised its stake in Can-Fite BioPharma stock. Armistice Capital LLC increased its stake in shares of Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 518,853 shares of the company’s stock after buying an additional 136,055 shares during the quarter. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent quarter. 21.00% of the stock is owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.